Meiling Li

Dr. Meiling Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YLYuchen Liu
Yuchen Liu
HJHaixu Jiang
Haixu Jiang
TKTianlun Kang
Tianlun Kang
XSXiaojun Shi
Xiaojun Shi
XLXiaoping Liu
Xiaoping Liu
MLMeiling Li
Meiling Li
Background and aim: Rheumatoid arthritis (RA) is an autoinflammatory disease that may lead to severe disability. The diagnosis of RA is limited due to the need for biomarkers with both reliability and efficiency. Platelets are deeply involved in the pathogenesis of RA. Our study aims to identify the underlying mechanism and screening for related biomarkers.Methods: We obtained two microarray datasets (GSE93272 and GSE17755) from the GEO database. We performed Weighted correlation network analysis (WGCNA) to analyze the expression modules in differentially expressed genes identified from GSE93272. We used KEGG, GO and GSEA enrichment analysis to elucidate the platelets-relating signatures (PRS). We then used the LASSO algorithm to develop a diagnostic model. We then used GSE17755 as a validation cohort to assess the diagnostic performance by operating Receiver Operating Curve (ROC).Results: The application of WGCNA resulted in the identification of 11 distinct co-expression modules. Notably, Module 2 exhibited a prominent association with platelets among the differentially expressed genes (DEGs) analyzed. Furthermore, a predictive model consisting of six genes (MAPK3, ACTB, ACTG1, VAV2, PTPN6, and ACTN1) was constructed using LASSO coefficients. The resultant PRS model demonstrated excellent diagnostic accuracy in both cohorts, as evidenced by area under the curve (AUC) values of 0.801 and 0.979.Conclusion: We elucidated the PRSs occurred in the pathogenesis of RA and developed a diagnostic model with excellent diagnostic potential.

11 September 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
YGYafei Guo
Yafei Guo
MLMeiling Li
Meiling Li
YHYueqin Huang
Yueqin Huang
Background: Low dietary fiber intake is common in the US, despite its health benefits. Individuals with metabolic syndrome (MetS), at high cardiovascular risk, may benefit significantly from higher fiber, but its link to mortality in this group is unclear.Methods: We analyzed prospective data from 10,962 U.S. adults with MetS (NHANES 1999–2018, mean age 58.1). Baseline fiber intake (g/day) was assessed via 24-h recalls. MetS was defined by ATP III criteria. Mortality (all-cause, CVD-specific) was tracked via the National Death Index (median follow-up 102 months). Cox models estimated hazard ratios (HRs) for mortality associated with fiber intake, adjusted for demographics, socioeconomic status, lifestyle, and comorbidities.Results: Over follow-up, 2,617 deaths occurred (887 CVD-specific). Higher fiber intake was associated with significantly lower mortality. Our analysis suggested a potential threshold effect near 21.7 g/day of fiber intake. Below this, each additional 5 g fiber reduced all-cause mortality risk by 7% (HR = 0.93, 95% CI: 0.91–0.96, p < 0.0001). Comparing highest to lowest tertile intake, adjusted HRs were 0.80 (95% CI 0.72–0.89, p < 0.0001) for all-cause and 0.61 (0.51–0.73, p < 0.0001) for CVD mortality. Results were robust in sensitivity analyses.Conclusion: In U.S. adults with MetS, higher dietary fiber intake was associated with significantly lower all-cause and CVD mortality. Benefits were most pronounced at lower intakes, plateauing around 22 g/day, suggesting achieving moderate fiber intake near recommendations offers substantial survival benefits in this high-risk group.

20 July 2020 in Chinese Journal of Integrative Medicine
Verified
Journal Article
Closed access
PDF file
FMFu-Xue Meng
Fu-Xue Meng
XYXin Yang
Xin Yang
MLMeiling Li
Meiling Li


4 June 2026 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
HLHaifeng Liu
Haifeng Liu
DHDanye Han
Danye Han
MLMeiling Li
Meiling Li
Sodium‑glucose co‑transport protein inhibitor Sotagliflozin (SOTA) has demonstrated cardiovascular benefits in diabetic patients, while doxorubicin (DOX) is widely used to generate cardiomyopathy experimental models. The present study investigated the cardioprotective mechanisms of SOTA on DOX‑induced heart failure in vitro and in vivo. First, C57BL/6 mice were injected with multiple doses of DOX (total 15 mg/kg), and the in vivo impact of SOTA on cardiac function and cardiomyopathy‑related biochemical signaling was assessed. Next, H9C2 cells were treated with DOX in the presence of SOTA to examine the changes in cell viability, mitochondrial function, inflammation, oxidative stress and cell death‑related signal pathways. SOTA treatment in vivo alleviated cardiac dysfunction and fibrosis while reducing cardiomyocyte apoptosis, inflammation, oxidative stress and mitochondrial dysfunction. In vitro, H9c2 cells exposed to DOX in the presence of SOTA exhibited enhanced cell viability and mitigated apoptosis, inflammation, oxidative stress and mitochondrial damage. Furthermore, cleaved caspase‑3 and inflammatory cytokine (IL‑6, IL‑1β and TNF‑α) levels were decreased. Reactive oxygen species and mitochondrial Ca2+ loading were reduced. Mitochondrial dysfunction was also improved, as indicated by increased JC‑1 aggregates and Bcl‑2/Bax ratios. Notably, SOTA activated 5' AMP‑activated protein kinase (AMPK) and inhibited mTOR signaling while protecting from DOX‑induced cardiomyopathy, suggesting SOTA as a promising therapeutic for heart failure treatment.

16 July 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
MSMinhui Su
Minhui Su
HJHaixu Jiang
Haixu Jiang
SLShengyan Liu
Shengyan Liu
PSPengfei Shen
Pengfei Shen
DZDinghua Zhou
Dinghua Zhou
MLMeiling Li
Meiling Li
Objectives: The coronavirus disease (COVID-19) pandemic has potentially impacted the care of patients with rheumatic diseases, including Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome. We investigates the effects on clinical characteristics, potential factors, and outcomes in SAPHO patients during the COVID-19 pandemic.Methods: SAPHO patients were recruited for this cross-sectional study from Fangshan Hospital of Beijing University of Chinese Medicine. In total, 375 patients (mean age, 47.5 years, 72.53% females) were asked about demographic data, disease status, current treatments, and clinical manifestations during the epidemic, and potential relationships were analyzed.Results: Among 375 included patients, 329 were infected with coronavirus 2019. Compared with non-infected patients, infected ones were more likely to have higher disease activity (p = 0.006). However, Janus kinase (JAK) inhibitor use was lower in detected COVID-19 cases than in non-infected cases in our cohort. Disease symptoms during COVID-19 were more commonly present in the non-JAK group than JAK groups, including rhinorrhea (p = 0.030), nasal congestion (p = 0.023), sore throat (p = 0.042), pneumonia (p = 0.044), headache (p = 0.023), and prevalence of palpitation (p = 0.015). In this study, 29 participants underwent tonsillectomy. Tonsillectomized patients showed a significantly higher prevalence of pneumonia than patients who did not undergo tonsillectomy (p = 0.009). The associated effect factors were displayed in the case of previous tonsillectomy using multivariate analysis and Firth’s penalized likelihood. JAK inhibitor use (p = 0.025) and pneumonia (p = 0.011) were more likely to develop in patients with a history of tonsillectomy.Conclusion: Disease activity was inversely correlated with JAK inhibitor use in SAPHO patients with COVID-19 during the pandemic. Thus, JAK antagonists have protective effects on SAPHO patients with infections and can significantly mitigate new clinical crown symptoms. However, there was a significant negative correlation between tonsillectomy and the prevalence of SAPHO with COVID-19, which demonstrates that tonsillectomy may be associated with an increased risk of COVID-19 adverse outcomes, especially in cases of taste disorders and pneumonia.